Johnson & Johnson to offer four prescription medicines on TrumpRx website

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/26/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. PRME

April 24, 2026 4:57 PM EDT

FILE PHOTO: People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov/File Photo

By Padmanabhan Ananthan

April ‌24 (Reuters) - Johnson & ​Johnson ​will start selling four of its medications on the Trump administration's ‌TrumpRx website, the company told Reuters ⁠on Friday.

The company said it would begin offering ‌its diabetes drugs Invokamet, ‌Invokamet XR and Invokana, as well as blood thinner Xarelto, through the TrumpRx platform ​and its direct‑to‑consumer website, JNJ Direct.

The healthcare conglomerate voluntarily reached an agreement ⁠with the Trump administration in January to reduce drug prices ​for Americans, expanding access to affordable prescriptions under Medicaid and marketing its ​products on the TrumpRx ‌platform in exchange for an exemption from the administration's tariffs.

Other drugmakers ⁠including Pfizer , Novo Nordisk , Eli Lilly and AstraZeneca have entered into similar deals tied to TrumpRx or ⁠so‑called "most‑favoured‑nation" pricing aimed at lowering U.S. drug costs ​and encouraging domestic production.

TrumpRx is meant to serve cash‑paying patients with valid prescriptions, including uninsured consumers and ‌those whose insurance does not cover a particular drug.

Johnson & Johnson previously ‌pledged $55 billion in research and production, ⁠including facilities in ‌Pennsylvania and North ​Carolina.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore and Maju ‌Samuel)


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters